Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue SUPPL. 1, 2010, Pages

  Giladi, Nis ^b,c   Kazanov, Diana ^b   Shpitz, Baruch ^a,c   Aroch, Ilan ^b,c   Kraus, Sarah ^b,c   Arber, Nadir ^b,c  

^a Sapir Medical Center   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemoprevention; Colorectal cancer; Curcumin; Non steroidal anti inflammatory drug; Sulindac sulfone

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CURCUMIN; LIPOCORTIN 5; SULINDAC SULFONE;

ABERRANT CRYPT FOCI; ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CRYPT CELL; CYTOTOXICITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CRYPT; LOW DRUG DOSE; MALE; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HT29 CELLS; HUMANS; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, WISTAR; SULINDAC;

EID: 77950669357     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003718841     Document Type: Conference Paper

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225-234
2. Greenwald P, Kelloff GJ. The role of chemoprevention in cancer control. IARC Sci 1996;139:13-22
3. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999;59:597-601
4. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955-1968
5. Ringman John M, Frautschy Sally A, Cole Gregory M, et al. Potential role of the curry spice curcumin in Alzheimer's disease. L. Curr Alzheimer Res 2005;2:131-136
6. Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 1999;19:3675-3680
7. Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa beta activation. Mutat Res 2001;480-481:243-268
8. Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002;21:8414-8427
9. Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005;11:6738-6744
10. Lev-Ari S, Zinger H, Kazanov D, et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 2005;59:S276-80
11. Lev-Ari S, Strier L, Lichtenberg D, et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 2006;45:171-177
12. Shpitz B, Giladi N, Sagiv E, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006;74:140-144
13. Shen TY, Winter CA. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res 1977;12:90-245
14. Exisulind: aptosyn, FGN 1, prevatac, sulindac sulfone. Drugs R D 2004;5:220-226
15. Thompson HI, Briggs S, Paranka NS, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Nat Cancer Inst 1995;87:1259-1260
16. Reddy BS, Kawamori T, Lubet RA. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999;59:3387-3391
17. Kim KP, Whitehead C, Piazza G, Wargovich MJ. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004;24:1805-1811
18. Thompson HJ, Jiang C, Lu J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57:267-271
19. Goldberg Y, Nassif II, Pittas A. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996;12:893-901
20. Burke C, van Stolk R, Arber N, et al. Exisulind prevents adenoma formation in familial adenomatous polyposis (FAP). Gastroenterology 2000;118:A657
21. Arber N, Kuwada S, Leshno M, et al. Exisulind Study Group. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut 2006;55:367-373
22. Arber N, Sutter T, Miyake M, et al. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene 1996;12:1903-1908
23. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51
24. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-151
25. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-1028
26. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-6854
27. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-398
28. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006;4:1035-1038
29. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-2915
30. Minami T, Adachi M, Kawamura R, et al. Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res 2005;11:5248-5256
31. Ohishi T, Kishimoto Y, Miura N. Synergistic effects of (-) epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett 2002;177:49-56
32. Chan DC, Earle KA, Zhao TL. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002;8:904-912
33. Soriano AF, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59:6178-6184